查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1832491

心臟生物标记市场（按生物标记类型、临床环境、应用和最终用户划分）—全球预测 2025-2032

Cardiac Biomarker Market by Biomarker Type, Clinical Setting, Application, End User - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 194 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年心臟生物标记市场将成长至 270.9 亿美元，复合年增长率为 9.33%。

主要市场统计数据
基准年2024年 132.6亿美元
预计2025年 144.1亿美元
预测年份：2032年 270.9亿美元
复合年增长率（%） 9.33%

对不断变化的临床需求和技术期望的基础概述，这些需求和技术期望将决定心臟生物标记诊断的未来发展轨迹

心臟生物标记领域正处于临床需求与技术创新的交会点，其驱动力在于对更快、更精准的诊断方法和更完善的病患诊疗路径的需求。临床上越来越重视急性心臟疾病的早期检测，以及对更精准风险分层的需求，使得生物标记检测从辅助手段提升为急性和慢性心臟疾病护理的核心组成部分。因此，包括临床实验室、医院系统和诊断设备製造商在内的相关人员正在重新评估其检测组合、操作流程和照护现场部署策略，以适应不断发展的临床方案。

此外，监管审查和品质期望不断提高，迫使检测开发人员和临床实验室优先考虑分析灵敏度、特异性和可重复性。新平台强调与电子健康记录和决策支援工具的集成，使临床医生能够根据即时患者数据解读生物标记结果。在这种环境下，关于技术采用、伙伴关係和临床检验的策略决策成为区分产品和实现患者预后可衡量改善的关键因素。因此，领导者在製定未来投资决策时，必须平衡临床效用、营运可行性和监管准备度。

关键的技术、临床和营运曲折点将加速创新并改变医疗保健系统对心臟生物标记解决方案的采用

近期趋势正在推动变革，重新定义心臟生物标记的开发、检验及其在护理路径中的应用。高灵敏度免疫测量正在改变诊断阈值，从而能够更早发现心肌损伤。同时，分散式检查模式的普及也挑战了传统的以实验室为中心的模式，使其能够更快速地做出更贴近患者的决策。这些结构性变化也对采购、培训和报销考量产生了影响。

同时，数位整合和进阶分析技术正开始放大生物标记数据的价值。机器学习模型越来越多地用于解读连续生物标记测量值以及临床参数，从而提高诊断准确性和风险分层。多重检测和基于面板的检测作用日益增强，既带来了机会，也带来了复杂性，因此需要跨学科验证和统一的检测标准。为此，製造商和临床领导者正在寻求伙伴关係，以简化工作流程、检验临床效用，并确保将创新转化为实用且可部署的解决方案，从而增强医疗服务。

2025年美国贸易行动如何重塑心臟生物标记相关人员的筹资策略、供应弹性和业务连续性的全面评估

政策环境和贸易动态为依赖跨境试剂、设备和耗材供应链的製造商、经销商和临床实验室带来了新的考量。 2025年实施的关税变化和贸易措施迫使企业重新评估筹资策略、库存管理和供应商多元化。因此，采购团队强调供应弹性、组件在地化和合约弹性，以保持关键试剂供应的连续性。

实际上，这些关税主导的压力正在影响成本结构和供应商选择，但临床证据要求并未改变。实验室和卫生系统已做出回应，强调选择经过验证的替代供应商，延长前置作业时间规划，并加强常用试剂的库存管理。对于製造商而言，关税趋势增加了他们对区域製造伙伴关係的兴趣，并加速了契约製造製造商的加入，以最大限度地降低政策波动带来的风险。展望未来，积极调整采购网络并投资冗余供应路线的公司，在贸易条件波动的情况下，更有可能更好地维持临床营运和市场应对力。

细分市场主导的情报揭示了生物标记类型、临床应用和最终用户如何寻求客製化的监管和商业化途径

细緻的细分观点揭示了生物标记类型、临床环境、应用和最终用户之间的差异动态，指南靶向策略。生物标记特异性发展包括：在高灵敏度检测的推动下，肌钙蛋白在临床上持续受到重视；而脑钠肽 (BNP) 和 NT-proBNP 在心臟衰竭管理和预后监测方面持续受到关注。肌酸激酶 (CK) MB 和肌红蛋白在特定诊断情况下以及作为多重方法的一部分仍然发挥作用，尤其是在连续测量为临床决策提供资讯的情况下。

临床实务的不同之处在于，虽然实验室检测仍然是高通量、标准化分析的支柱，就地检验可提供快速的现场结果，从而改变急诊和急性护理工作流程。诊断需要对急性冠状动脉症候群、郁血性心臟衰竭衰竭和心肌梗塞途径进行快速分析和严格的临床检验；预后预测需要可重复性和纵向一致性；风险评估需要将生物标记结果与临床模型相结合以指导预防策略。此外，最终用户的情况决定了上市策略，因为诊断实验室优先考虑吞吐量和标准化，医院和诊所优先考虑整合工作流程和解释支持，而研究机构优先考虑新型生物标誌物的发现和转化验证。因此，产品开发、商业性推广和临床检验计划必须根据每个细分市场的独特需求和标准进行客製化，以最大限度地提高临床应用率并适应实践。

区域策略差异化突显了美洲、欧洲、中东和非洲以及亚太地区各自不同的临床监管和供应链需求

区域模式对技术采用、临床实务和供应链设计具有重要意义。在美洲，医疗保健系统重视快速的急性护理决策和广泛部署高灵敏度检测，这得益于成熟的实验室网路和对分散式检查模式日益增长的兴趣。该地区的相关人员通常优先考虑与大型医疗保健资讯系统的集成，并遵守推动检测性能预期的监管标准。

欧洲、中东和非洲展现出多样化的采用模式，领先的临床中心通常主导新型检测方法和分散式检查的采用，而其他市场则优先考虑成本效益和扩充性。在这个复杂的地区，法律规范和报销途径差异很大，影响着商业化时间表和临床检验策略。亚太地区以对本地製造能力的投资和对即时诊断解决方案的快速采用而着称，在多个市场，受大量患者群体和政府主导的诊断​​倡议的推动，这些市场正在积极采用。在各个地区，那些根据当地临床实践、监管细节和供应链现实情况量身定制部署策略的公司，很可能找到永续采用和协作的最佳途径。

竞争和合作概况揭示了成熟的检测供应商和敏捷的创新者如何部署临床证据製造和伙伴关係关係以获得诊断有效性

心臟生物标记诊断领域的竞争态势反映出，现有的检测供应商和敏捷的创新者都在寻求透过提升分析能力、整合工作流程和去中心化能力来实现临床差异化。现有企业通常利用广泛的分销网络、多年的临床检验数据和整合平台来维护大型医疗系统和参考实验室的信任。同时，规模较小的公司和新参与企业则专注于高灵敏度检测、照护现场设备以及与临床试验网络的合作，以建立证据基础，支持其在急诊和门诊环境中的应用。

策略联盟和原始设备製造商 (OEM) 关係持续影响产品的供应和地理覆盖范围。具有前瞻性的公司会投资于临床伙伴关係，以促进真实世界检验和增强结果解读的数位化工具。在营运方面，拥有强大品质系统、透明供应链和敏捷上市后支援的公司正在创造竞争优势。因此，有效的策略应将严格的临床证据产生、可扩展的生产方法和以客户为中心的服务模式结合，以确保在不同的医疗环境中持续采用。

製造商实验室和医疗保健领导者需要采取切实可行的策略措施，以协调供应弹性和临床检验的数位化集成，从而实现持续采用

产业领导者可以透过将产品蓝图与临床工作流程结合，并增强供应链对政策和物流中断的韧性，来加速价值创造。优先考虑与电子健康记录和决策支援系统的互通性，可以减少临床应用过程中的摩擦，并提高生物标记结果的可操作价值。此外，投资于证明其在关键用例（尤其是急性冠状动脉症候群、郁血性心臟衰竭衰竭和心肌梗塞途径）中效用的临床检验研究，可以增强临床医生的信心和支付方的认可。

在营运方面，製造商和实验室网路应多元化其供应商关係，并考虑建立区域或製造外包关係，以降低关税和物流风险。销售和医学事务团队应制定针对诊断实验室、医院、诊所和研究机构的有针对性的推广计划，重点关注检测性能、工作流程整合和真实世界证据。最后，透过上市后监测和客户回馈循环进行迭代产品改进，可以实现持续改进，并加强与临床相关人员的长期伙伴关係。

透明的混合方法结合了临床医生访谈、文献综述、监管分析和情境评估，确保了我们的研究结果的临床和操作严谨性

这项执行分析背后的研究将多源证据收集与结构化的定性和定量方法相结合，以确保研究结果的稳健性和可重复性。主要研究包括对临床实验室主任、循环系统、采购主管和行业高管的访谈，以了解关于检测性能、工作流程整合和应用障碍的当代观点。次要研究包括同行评审的临床文献、监管指导文件和公开的临床试验註册库，以支持临床效用声明和分析性能特征。

资料整合包括对主要访谈记录进行主题分析，并与二手资料进行交叉验证，以识别趋同趋势和特定地区的细微差别。透过情境分析，评估了供应链和政策影响，并考虑了替代采购配置以及关税对筹资策略的影响。在整个调查方法中，我们关注临床相关性、营运可行性和监管环境，以提供切实可行且符合当地决策要求的见解。

简要总结临床创新供应链弹性和有针对性的证据策略如何共同决定心臟生物标记部署的成功

摘要：心臟生物标记诊断正处于关键的十字路口，检测创新、数位整合和供应链策略正在重塑临床实践。高灵敏度侦测和分散式检查模式正在重新定义诊断时间表，并加快护理路径。同时，不断变化的贸易动态凸显了在地化供应弹性和策略伙伴关係关係的重要性。同时，针对特定细分市场的考量，包括生物标记类型、临床环境、应用和最终用户，凸显了製定客製化开发和商业化策略的必要性。

为了充分发挥生物标记主导医学的潜力，决策者应优先考虑临床证据生成、互通性和营运敏捷性。那些将技术创新与实际部署策略相结合，并积极与临床医生和实验室负责人合作的公司，将最有能力将科学进步转化为改善的患者治疗效果。最终，严谨的、循证的产品开发和市场准入方法将创造持久的临床价值和竞争优势。

目录

第一章：前言

第二章调查方法

第三章执行摘要

第四章 市场概况

第五章 市场洞察

  • 高敏感性肌钙蛋白检测的广泛应用使得心肌梗塞的早期发现和风险分层成为可能
  • 照护现场心臟生物标记检测与远端医疗平台结合，实现远端患者监护
  • 扩展结合NT-proBNP、肌钙蛋白和发炎标记的多重生物标记组，以改善心臟衰竭诊断
  • 开发超灵敏数位免疫检测，用于评估癌症患者的潜在心臟毒性
  • 新兴的人工智慧驱动预测演算法利用纵向生物标记数据预测急性心臟事件
  • 新型心臟生物标记检测方法获得监管部门核准，推动报销和扩大临床应用

第六章：2025年美国关税的累积影响

第七章：人工智慧的累积影响，2025年

8. 心臟生物标记市场（依生物标记类型）

  • BNP和NT-proBNP
  • 肌酸激酶（CK）MB
  • 肌红蛋白
  • 肌钙蛋白

9. 心臟生物标记市场（依临床状况）

  • 实验室检查
  • 就地检验

第 10 章：心臟生物标记市场（按应用）

  • 诊断
    • 急性冠状动脉症候群
    • 郁血性心臟衰竭衰竭
    • 心肌梗塞
  • 预后
  • 风险评估

第 11 章：心臟生物标记市场（按最终用户）

  • 诊断实验室
  • 医院和诊所
  • 研究机构

第 12 章：心臟生物标记市场（按地区）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第 13 章：心臟生物标记市场（按类别）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第 14 章：各国心臟生物标记市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十五章 竞争格局

  • 2024年市占率分析
  • 2024年FPNV定位矩阵
  • 竞争分析
    • Abbott Laboratories
    • Abcam plc
    • Becton, Dickinson and Company
    • Bio-Rad Laboratories Inc.
    • bioMerieux SA
    • Danaher Corporation
    • DiaSorin SpA
    • Epitope Diagnostics Inc.
    • F. Hoffmann-La Roche AG
    • Fujirebio Diagnostics Inc.
    • Guangzhou Wondfo Biotech Co., Ltd.
    • Hologic Inc.
    • Johnson & Johnson Services, Inc.
    • Life Diagnostics, Inc.
    • LSI Medience Corporation
    • Meridian Bioscience, Inc.
    • Myriad RBM Inc.
    • PerkinElmer, Inc.
    • Quest Diagnostics Incorporated
    • Quidel Corporation
    • QuidelOrtho Corporation
    • Randox Laboratories Limited
    • Sekisui Medical Co., Ltd.
    • Siemens Healthineers AG
    • Singulex, Inc.
    • Sysmex Corporation
    • Thermo Fisher Scientific Inc.
    • Tosoh Corporation
    • Trinity Biotech plc
Product Code: MRR-433AB1DC288D

The Cardiac Biomarker Market is projected to grow by USD 27.09 billion at a CAGR of 9.33% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 13.26 billion
Estimated Year [2025] USD 14.41 billion
Forecast Year [2032] USD 27.09 billion
CAGR (%) 9.33%

Foundational overview of evolving clinical demands and technological expectations shaping the future trajectory of cardiac biomarker diagnostics

The cardiac biomarker landscape sits at the intersection of clinical necessity and technological innovation, driven by the need for faster, more accurate diagnostics and improved patient pathways. Rising clinical emphasis on early detection of acute cardiac events and the demand for more precise risk stratification have elevated biomarker testing from a supportive role to a central component of emergent and chronic cardiac care. As a result, stakeholders across clinical laboratories, hospital systems, and diagnostic manufacturers are re-evaluating assay portfolios, operational workflows, and point-of-care deployment strategies to align with evolving clinical protocols.

Moreover, regulatory scrutiny and quality expectations have heightened, prompting assay developers and clinical laboratories to prioritize analytical sensitivity, specificity, and reproducibility. Emerging platforms emphasize integration with electronic health records and decision support tools, enabling clinicians to interpret biomarker results in the context of real-time patient data. In this environment, strategic decisions about technology adoption, partnerships, and clinical validation become decisive factors in differentiating offerings and delivering measurable improvements in patient outcomes. Consequently, leaders must balance clinical utility, operational feasibility, and regulatory readiness when shaping future investments.

Key technological, clinical, and operational inflection points that are accelerating innovation and altering health system adoption of cardiac biomarker solutions

Recent years have produced transformative shifts that are redefining how cardiac biomarkers are developed, validated, and used in care pathways. High-sensitivity immunoassays have altered diagnostic thresholds and enabled earlier detection of myocardial injury, which in turn changes clinical algorithms for emergency departments and ambulatory care. Simultaneously, the proliferation of decentralized testing models is challenging traditional laboratory-centric paradigms by enabling rapid decision-making closer to the patient. These structural changes ripple across procurement, training, and reimbursement considerations.

Concurrently, digital integration and advanced analytics have begun to amplify the value of biomarker data. Machine learning models increasingly assist in interpreting serial biomarker measurements alongside clinical parameters, thereby improving diagnostic accuracy and risk stratification. The expanding role of multiplexed and panel-based testing introduces both opportunity and complexity, requiring cross-disciplinary validation and harmonized laboratory standards. In response, manufacturers and clinical leaders are pursuing partnerships to streamline workflows, validate clinical utility, and ensure that innovations translate into practical, deployable solutions that enhance care delivery.

Comprehensive assessment of how 2025 United States trade measures are reshaping procurement strategies supply resilience and operational continuity for cardiac biomarker stakeholders

The policy environment and trade dynamics have introduced new considerations for manufacturers, distributors, and clinical laboratories that rely on cross-border supply chains for reagents, instruments, and consumables. Tariff changes and trade measures implemented in 2025 have compelled organizations to revisit sourcing strategies, inventory management, and supplier diversification. As a result, procurement teams have intensified focus on supply resilience, component localization, and contractual flexibility to maintain continuity of critical assay availability.

In practice, these tariff-driven pressures influence cost structures and supplier selection without altering clinical evidence requirements. Laboratories and health systems have responded by increasing their emphasis on validated alternate suppliers, longer lead-time planning, and tighter inventory controls for high-use reagents. For manufacturers, the tariff landscape has accelerated interest in regional manufacturing partnerships and qualification of additional contract manufacturers to minimize exposure to policy volatility. Looking ahead, firms that proactively adapt procurement networks and that invest in redundant supply paths will better preserve clinical operations and market responsiveness under fluctuating trade conditions.

Segment-driven intelligence revealing how biomarker types clinical settings applications and end users demand tailored development regulatory and commercialization pathways

A nuanced view of segmentation uncovers differential dynamics across biomarker type, clinical setting, application, and end user that should guide targeted strategies. Biomarker-specific developments include sustained clinical emphasis on troponins driven by high-sensitivity assays, while BNP and NT-proBNP continue to command attention for heart failure management and prognostic monitoring. Creatine Kinase (CK) MB and myoglobin retain roles in specific diagnostic contexts and as part of multiplexed approaches, particularly where serial measurements inform clinical decisions.

Clinical setting distinctions matter because laboratory testing remains the backbone for high-throughput, standardized analysis, whereas point of care testing delivers rapid, on-site results that shift emergency and acute care workflows. Application-driven priorities vary by use case: diagnosis requires rapid analytic turnaround and stringent clinical validation across acute coronary syndrome, congestive heart failure, and myocardial infarction pathways; prognosis demands reproducibility and longitudinal consistency; and risk assessment integrates biomarker results with clinical models to guide preventative strategies. End user profiles also dictate go-to-market tactics, as diagnostic laboratories focus on throughput and standardization, hospitals and clinics prioritize integrated workflows and interpretive support, and research institutes emphasize novel biomarker discovery and translational validation. Consequently, product development, commercial outreach, and clinical validation programs should align with the unique needs and decision criteria of each segment to maximize clinical adoption and operational fit.

Regional strategic differentiation highlighting how the Americas Europe Middle East & Africa and Asia-Pacific each present distinct clinical regulatory and supply chain imperatives

Regional patterns exert a significant influence on technology adoption, clinical practice, and supply chain design. In the Americas, health systems emphasize rapid acute care decision-making and broad deployment of high-sensitivity assays, supported by established laboratory networks and growing interest in decentralized testing models. Stakeholders in this region typically prioritize integration with large health information systems and adherence to regulatory standards that drive assay performance expectations.

Europe, Middle East & Africa exhibits heterogeneous adoption patterns where advanced clinical centers often lead in implementing novel assays and decentralized testing, while other markets emphasize cost-effectiveness and scalability. Regulatory frameworks and reimbursement pathways vary widely across this combined region, which shapes commercialization timelines and clinical validation strategies. In the Asia-Pacific region, investment in local manufacturing capabilities and rapid adoption of point-of-care solutions are prominent, with several markets demonstrating aggressive uptake driven by high patient volumes and government-led diagnostics initiatives. Across all regions, companies that tailor deployment strategies to regional clinical practice, regulatory nuance, and supply chain realities will find the strongest pathways to sustainable adoption and collaboration.

Competitive and collaborative profiles that reveal how incumbent assay providers and nimble innovators deploy clinical evidence manufacturing and partnerships to capture diagnostic relevance

Competitive dynamics in cardiac biomarker diagnostics reflect both entrenched assay providers and agile innovators seeking clinical differentiation through improved analytics, workflow integration, and decentralized capabilities. Established players typically leverage broad distribution networks, long-standing clinical validation data, and integrated platforms to maintain trust among large health systems and reference laboratories. At the same time, smaller companies and new entrants concentrate on high-sensitivity assays, point-of-care instrumentation, and partnering with clinical trial networks to build evidence that supports adoption in acute and ambulatory settings.

Strategic alliances and OEM relationships continue to shape product availability and geographic reach. Forward-looking organizations invest in clinical partnerships that expedite real-world validation and in digital tools that enhance result interpretation. From an operational standpoint, companies that demonstrate robust quality systems, transparent supply chains, and rapid post-market support create competitive advantage. Consequently, effective strategies combine rigorous clinical evidence generation, scalable manufacturing approaches, and customer-centric service models to secure sustained adoption across diverse healthcare environments.

Actionable strategic imperatives for manufacturers laboratories and healthcare leaders to harmonize clinical validation supply resilience and digital integration for durable adoption

Industry leaders can accelerate value creation by aligning product roadmaps with clinical workflows and by strengthening supply chain resilience to withstand policy and logistic disruptions. Prioritizing interoperability with electronic health records and decision-support systems will reduce friction in clinical adoption and improve the actionable value of biomarker results. In addition, investing in clinical validation studies that demonstrate utility across key use cases-particularly acute coronary syndrome, congestive heart failure, and myocardial infarction pathways-will support broader clinician confidence and payer recognition.

Operationally, manufacturers and laboratory networks should diversify supplier relationships and consider regional manufacturing or contract manufacturing partnerships to reduce exposure to tariff-driven or logistical risks. Sales and medical affairs teams should build targeted outreach programs tailored to diagnostic laboratories, hospitals and clinics, and research institutes, emphasizing assay performance, workflow integration, and real-world evidence. Finally, embracing iterative product improvement through post-market surveillance and customer feedback loops will enable continuous refinement and stronger long-term partnerships with clinical stakeholders.

Transparent mixed-methods approach combining clinician interviews literature review regulatory analysis and scenario evaluation to ensure clinical and operational rigor in findings

The research behind this executive analysis combines multi-source evidence collection with structured qualitative and quantitative methods to ensure robust, reproducible findings. Primary research encompassed interviews with clinical laboratory directors, cardiology specialists, procurement leaders, and industry executives to capture contemporary perspectives on assay performance, workflow integration, and adoption barriers. Secondary research included peer-reviewed clinical literature, regulatory guidance documents, and publicly available clinical trial registries to corroborate clinical utility claims and analytical performance characteristics.

Data synthesis applied thematic analysis to primary interview transcripts and cross-validation against secondary sources to identify convergent trends and region-specific nuances. Supply chain and policy implications were evaluated through scenario analysis that considers alternative sourcing configurations and tariff impacts on procurement strategies. Throughout the methodology, emphasis remained on clinical relevance, operational feasibility, and regulatory context to produce insights that are both actionable and aligned with frontline decision-making requirements.

Concise synthesis of how clinical innovation supply chain resilience and targeted evidence strategies collectively determine success in cardiac biomarker deployment

In summary, cardiac biomarker diagnostics stand at a pivotal juncture where assay innovation, digital integration, and supply chain strategy converge to reshape clinical practice. High-sensitivity assays and decentralized testing models are redefining diagnostic timelines and enabling more responsive care pathways, while evolving trade dynamics underscore the importance of localized supply resilience and strategic partnerships. At the same time, segmentation-specific considerations across biomarker type, clinical setting, application, and end user highlight the necessity of tailored development and commercialization strategies.

Decision-makers should prioritize clinical evidence generation, interoperability, and operational agility to capture the full potential of biomarker-driven care. Firms that align technical innovation with pragmatic deployment strategies and that engage proactively with clinicians and laboratory leaders will be best positioned to convert scientific advances into improved patient outcomes. Ultimately, a disciplined, evidence-based approach to product development and market engagement will create enduring clinical value and competitive differentiation.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Rising adoption of high-sensitivity troponin assays enabling earlier myocardial infarction detection and risk stratification
  • 5.2. Integration of point-of-care cardiac biomarker testing with telemedicine platforms for remote patient monitoring
  • 5.3. Expansion of multiplex biomarker panels combining NT-proBNP, troponin, and inflammatory markers for improved heart failure diagnosis
  • 5.4. Development of ultra-sensitive digital immunoassays for subclinical cardiotoxicity assessment in oncology patients
  • 5.5. Emergence of AI-driven predictive algorithms using longitudinal biomarker data to forecast acute cardiac events
  • 5.6. Regulatory approvals of novel cardiac biomarker assays driving reimbursement and broader clinical adoption

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Cardiac Biomarker Market, by Biomarker Type

  • 8.1. BNP & NT-proBNP
  • 8.2. Creatine Kinase (CK) MB
  • 8.3. Myoglobin
  • 8.4. Troponins

9. Cardiac Biomarker Market, by Clinical Setting

  • 9.1. Laboratory Testing
  • 9.2. Point Of Care Testing

10. Cardiac Biomarker Market, by Application

  • 10.1. Diagnosis
    • 10.1.1. Acute Coronary Syndrome
    • 10.1.2. Congestive Heart Failure
    • 10.1.3. Myocardial Infarction
  • 10.2. Prognosis
  • 10.3. Risk Assessment

11. Cardiac Biomarker Market, by End User

  • 11.1. Diagnostic Laboratories
  • 11.2. Hospitals & Clinics
  • 11.3. Research Institutes

12. Cardiac Biomarker Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Cardiac Biomarker Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Cardiac Biomarker Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2024
  • 15.2. FPNV Positioning Matrix, 2024
  • 15.3. Competitive Analysis
    • 15.3.1. Abbott Laboratories
    • 15.3.2. Abcam plc
    • 15.3.3. Becton, Dickinson and Company
    • 15.3.4. Bio-Rad Laboratories Inc.
    • 15.3.5. bioMerieux SA
    • 15.3.6. Danaher Corporation
    • 15.3.7. DiaSorin S.p.A.
    • 15.3.8. Epitope Diagnostics Inc.
    • 15.3.9. F. Hoffmann-La Roche AG
    • 15.3.10. Fujirebio Diagnostics Inc.
    • 15.3.11. Guangzhou Wondfo Biotech Co., Ltd.
    • 15.3.12. Hologic Inc.
    • 15.3.13. Johnson & Johnson Services, Inc.
    • 15.3.14. Life Diagnostics, Inc.
    • 15.3.15. LSI Medience Corporation
    • 15.3.16. Meridian Bioscience, Inc.
    • 15.3.17. Myriad RBM Inc.
    • 15.3.18. PerkinElmer, Inc.
    • 15.3.19. Quest Diagnostics Incorporated
    • 15.3.20. Quidel Corporation
    • 15.3.21. QuidelOrtho Corporation
    • 15.3.22. Randox Laboratories Limited
    • 15.3.23. Sekisui Medical Co., Ltd.
    • 15.3.24. Siemens Healthineers AG
    • 15.3.25. Singulex, Inc.
    • 15.3.26. Sysmex Corporation
    • 15.3.27. Thermo Fisher Scientific Inc.
    • 15.3.28. Tosoh Corporation
    • 15.3.29. Trinity Biotech plc

LIST OF FIGURES

  • FIGURE 1. GLOBAL CARDIAC BIOMARKER MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL CARDIAC BIOMARKER MARKET SIZE, BY BIOMARKER TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL CARDIAC BIOMARKER MARKET SIZE, BY BIOMARKER TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL CARDIAC BIOMARKER MARKET SIZE, BY CLINICAL SETTING, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL CARDIAC BIOMARKER MARKET SIZE, BY CLINICAL SETTING, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL CARDIAC BIOMARKER MARKET SIZE, BY APPLICATION, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL CARDIAC BIOMARKER MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL CARDIAC BIOMARKER MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL CARDIAC BIOMARKER MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL CARDIAC BIOMARKER MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 11. AMERICAS CARDIAC BIOMARKER MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. NORTH AMERICA CARDIAC BIOMARKER MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. LATIN AMERICA CARDIAC BIOMARKER MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. EUROPE, MIDDLE EAST & AFRICA CARDIAC BIOMARKER MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. EUROPE CARDIAC BIOMARKER MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. MIDDLE EAST CARDIAC BIOMARKER MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. AFRICA CARDIAC BIOMARKER MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC CARDIAC BIOMARKER MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. GLOBAL CARDIAC BIOMARKER MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASEAN CARDIAC BIOMARKER MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GCC CARDIAC BIOMARKER MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. EUROPEAN UNION CARDIAC BIOMARKER MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. BRICS CARDIAC BIOMARKER MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. G7 CARDIAC BIOMARKER MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. NATO CARDIAC BIOMARKER MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. GLOBAL CARDIAC BIOMARKER MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. CARDIAC BIOMARKER MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 28. CARDIAC BIOMARKER MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. CARDIAC BIOMARKER MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL CARDIAC BIOMARKER MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL CARDIAC BIOMARKER MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL CARDIAC BIOMARKER MARKET SIZE, BY BIOMARKER TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL CARDIAC BIOMARKER MARKET SIZE, BY BIOMARKER TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL CARDIAC BIOMARKER MARKET SIZE, BY BNP & NT-PROBNP, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL CARDIAC BIOMARKER MARKET SIZE, BY BNP & NT-PROBNP, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL CARDIAC BIOMARKER MARKET SIZE, BY BNP & NT-PROBNP, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL CARDIAC BIOMARKER MARKET SIZE, BY BNP & NT-PROBNP, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL CARDIAC BIOMARKER MARKET SIZE, BY BNP & NT-PROBNP, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL CARDIAC BIOMARKER MARKET SIZE, BY BNP & NT-PROBNP, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL CARDIAC BIOMARKER MARKET SIZE, BY CREATINE KINASE (CK) MB, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL CARDIAC BIOMARKER MARKET SIZE, BY CREATINE KINASE (CK) MB, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL CARDIAC BIOMARKER MARKET SIZE, BY CREATINE KINASE (CK) MB, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL CARDIAC BIOMARKER MARKET SIZE, BY CREATINE KINASE (CK) MB, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL CARDIAC BIOMARKER MARKET SIZE, BY CREATINE KINASE (CK) MB, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL CARDIAC BIOMARKER MARKET SIZE, BY CREATINE KINASE (CK) MB, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL CARDIAC BIOMARKER MARKET SIZE, BY MYOGLOBIN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL CARDIAC BIOMARKER MARKET SIZE, BY MYOGLOBIN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL CARDIAC BIOMARKER MARKET SIZE, BY MYOGLOBIN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL CARDIAC BIOMARKER MARKET SIZE, BY MYOGLOBIN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL CARDIAC BIOMARKER MARKET SIZE, BY MYOGLOBIN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL CARDIAC BIOMARKER MARKET SIZE, BY MYOGLOBIN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL CARDIAC BIOMARKER MARKET SIZE, BY TROPONINS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL CARDIAC BIOMARKER MARKET SIZE, BY TROPONINS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL CARDIAC BIOMARKER MARKET SIZE, BY TROPONINS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL CARDIAC BIOMARKER MARKET SIZE, BY TROPONINS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL CARDIAC BIOMARKER MARKET SIZE, BY TROPONINS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL CARDIAC BIOMARKER MARKET SIZE, BY TROPONINS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL CARDIAC BIOMARKER MARKET SIZE, BY CLINICAL SETTING, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL CARDIAC BIOMARKER MARKET SIZE, BY CLINICAL SETTING, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL CARDIAC BIOMARKER MARKET SIZE, BY LABORATORY TESTING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL CARDIAC BIOMARKER MARKET SIZE, BY LABORATORY TESTING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL CARDIAC BIOMARKER MARKET SIZE, BY LABORATORY TESTING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL CARDIAC BIOMARKER MARKET SIZE, BY LABORATORY TESTING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL CARDIAC BIOMARKER MARKET SIZE, BY LABORATORY TESTING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL CARDIAC BIOMARKER MARKET SIZE, BY LABORATORY TESTING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL CARDIAC BIOMARKER MARKET SIZE, BY POINT OF CARE TESTING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL CARDIAC BIOMARKER MARKET SIZE, BY POINT OF CARE TESTING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL CARDIAC BIOMARKER MARKET SIZE, BY POINT OF CARE TESTING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL CARDIAC BIOMARKER MARKET SIZE, BY POINT OF CARE TESTING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL CARDIAC BIOMARKER MARKET SIZE, BY POINT OF CARE TESTING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL CARDIAC BIOMARKER MARKET SIZE, BY POINT OF CARE TESTING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL CARDIAC BIOMARKER MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL CARDIAC BIOMARKER MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL CARDIAC BIOMARKER MARKET SIZE, BY DIAGNOSIS, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL CARDIAC BIOMARKER MARKET SIZE, BY DIAGNOSIS, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL CARDIAC BIOMARKER MARKET SIZE, BY DIAGNOSIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL CARDIAC BIOMARKER MARKET SIZE, BY DIAGNOSIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL CARDIAC BIOMARKER MARKET SIZE, BY DIAGNOSIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL CARDIAC BIOMARKER MARKET SIZE, BY DIAGNOSIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL CARDIAC BIOMARKER MARKET SIZE, BY DIAGNOSIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL CARDIAC BIOMARKER MARKET SIZE, BY DIAGNOSIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL CARDIAC BIOMARKER MARKET SIZE, BY ACUTE CORONARY SYNDROME, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL CARDIAC BIOMARKER MARKET SIZE, BY ACUTE CORONARY SYNDROME, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL CARDIAC BIOMARKER MARKET SIZE, BY ACUTE CORONARY SYNDROME, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL CARDIAC BIOMARKER MARKET SIZE, BY ACUTE CORONARY SYNDROME, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL CARDIAC BIOMARKER MARKET SIZE, BY ACUTE CORONARY SYNDROME, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL CARDIAC BIOMARKER MARKET SIZE, BY ACUTE CORONARY SYNDROME, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL CARDIAC BIOMARKER MARKET SIZE, BY CONGESTIVE HEART FAILURE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL CARDIAC BIOMARKER MARKET SIZE, BY CONGESTIVE HEART FAILURE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL CARDIAC BIOMARKER MARKET SIZE, BY CONGESTIVE HEART FAILURE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL CARDIAC BIOMARKER MARKET SIZE, BY CONGESTIVE HEART FAILURE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL CARDIAC BIOMARKER MARKET SIZE, BY CONGESTIVE HEART FAILURE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL CARDIAC BIOMARKER MARKET SIZE, BY CONGESTIVE HEART FAILURE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL CARDIAC BIOMARKER MARKET SIZE, BY MYOCARDIAL INFARCTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL CARDIAC BIOMARKER MARKET SIZE, BY MYOCARDIAL INFARCTION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL CARDIAC BIOMARKER MARKET SIZE, BY MYOCARDIAL INFARCTION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL CARDIAC BIOMARKER MARKET SIZE, BY MYOCARDIAL INFARCTION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL CARDIAC BIOMARKER MARKET SIZE, BY MYOCARDIAL INFARCTION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL CARDIAC BIOMARKER MARKET SIZE, BY MYOCARDIAL INFARCTION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL CARDIAC BIOMARKER MARKET SIZE, BY PROGNOSIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL CARDIAC BIOMARKER MARKET SIZE, BY PROGNOSIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL CARDIAC BIOMARKER MARKET SIZE, BY PROGNOSIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL CARDIAC BIOMARKER MARKET SIZE, BY PROGNOSIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL CARDIAC BIOMARKER MARKET SIZE, BY PROGNOSIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL CARDIAC BIOMARKER MARKET SIZE, BY PROGNOSIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL CARDIAC BIOMARKER MARKET SIZE, BY RISK ASSESSMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL CARDIAC BIOMARKER MARKET SIZE, BY RISK ASSESSMENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL CARDIAC BIOMARKER MARKET SIZE, BY RISK ASSESSMENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL CARDIAC BIOMARKER MARKET SIZE, BY RISK ASSESSMENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL CARDIAC BIOMARKER MARKET SIZE, BY RISK ASSESSMENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL CARDIAC BIOMARKER MARKET SIZE, BY RISK ASSESSMENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL CARDIAC BIOMARKER MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL CARDIAC BIOMARKER MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL CARDIAC BIOMARKER MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL CARDIAC BIOMARKER MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL CARDIAC BIOMARKER MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL CARDIAC BIOMARKER MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL CARDIAC BIOMARKER MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL CARDIAC BIOMARKER MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL CARDIAC BIOMARKER MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL CARDIAC BIOMARKER MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL CARDIAC BIOMARKER MARKET SIZE, BY HOSPITALS & CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL CARDIAC BIOMARKER MARKET SIZE, BY HOSPITALS & CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL CARDIAC BIOMARKER MARKET SIZE, BY HOSPITALS & CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL CARDIAC BIOMARKER MARKET SIZE, BY HOSPITALS & CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL CARDIAC BIOMARKER MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL CARDIAC BIOMARKER MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL CARDIAC BIOMARKER MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL CARDIAC BIOMARKER MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL CARDIAC BIOMARKER MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL CARDIAC BIOMARKER MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL CARDIAC BIOMARKER MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL CARDIAC BIOMARKER MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 107. AMERICAS CARDIAC BIOMARKER MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 108. AMERICAS CARDIAC BIOMARKER MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 109. AMERICAS CARDIAC BIOMARKER MARKET SIZE, BY BIOMARKER TYPE, 2018-2024 (USD MILLION)
  • TABLE 110. AMERICAS CARDIAC BIOMARKER MARKET SIZE, BY BIOMARKER TYPE, 2025-2032 (USD MILLION)
  • TABLE 111. AMERICAS CARDIAC BIOMARKER MARKET SIZE, BY CLINICAL SETTING, 2018-2024 (USD MILLION)
  • TABLE 112. AMERICAS CARDIAC BIOMARKER MARKET SIZE, BY CLINICAL SETTING, 2025-2032 (USD MILLION)
  • TABLE 113. AMERICAS CARDIAC BIOMARKER MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 114. AMERICAS CARDIAC BIOMARKER MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 115. AMERICAS CARDIAC BIOMARKER MARKET SIZE, BY DIAGNOSIS, 2018-2024 (USD MILLION)
  • TABLE 116. AMERICAS CARDIAC BIOMARKER MARKET SIZE, BY DIAGNOSIS, 2025-2032 (USD MILLION)
  • TABLE 117. AMERICAS CARDIAC BIOMARKER MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 118. AMERICAS CARDIAC BIOMARKER MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 119. NORTH AMERICA CARDIAC BIOMARKER MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 120. NORTH AMERICA CARDIAC BIOMARKER MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 121. NORTH AMERICA CARDIAC BIOMARKER MARKET SIZE, BY BIOMARKER TYPE, 2018-2024 (USD MILLION)
  • TABLE 122. NORTH AMERICA CARDIAC BIOMARKER MARKET SIZE, BY BIOMARKER TYPE, 2025-2032 (USD MILLION)
  • TABLE 123. NORTH AMERICA CARDIAC BIOMARKER MARKET SIZE, BY CLINICAL SETTING, 2018-2024 (USD MILLION)
  • TABLE 124. NORTH AMERICA CARDIAC BIOMARKER MARKET SIZE, BY CLINICAL SETTING, 2025-2032 (USD MILLION)
  • TABLE 125. NORTH AMERICA CARDIAC BIOMARKER MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 126. NORTH AMERICA CARDIAC BIOMARKER MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 127. NORTH AMERICA CARDIAC BIOMARKER MARKET SIZE, BY DIAGNOSIS, 2018-2024 (USD MILLION)
  • TABLE 128. NORTH AMERICA CARDIAC BIOMARKER MARKET SIZE, BY DIAGNOSIS, 2025-2032 (USD MILLION)
  • TABLE 129. NORTH AMERICA CARDIAC BIOMARKER MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 130. NORTH AMERICA CARDIAC BIOMARKER MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 131. LATIN AMERICA CARDIAC BIOMARKER MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 132. LATIN AMERICA CARDIAC BIOMARKER MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 133. LATIN AMERICA CARDIAC BIOMARKER MARKET SIZE, BY BIOMARKER TYPE, 2018-2024 (USD MILLION)
  • TABLE 134. LATIN AMERICA CARDIAC BIOMARKER MARKET SIZE, BY BIOMARKER TYPE, 2025-2032 (USD MILLION)
  • TABLE 135. LATIN AMERICA CARDIAC BIOMARKER MARKET SIZE, BY CLINICAL SETTING, 2018-2024 (USD MILLION)
  • TABLE 136. LATIN AMERICA CARDIAC BIOMARKER MARKET SIZE, BY CLINICAL SETTING, 2025-2032 (USD MILLION)
  • TABLE 137. LATIN AMERICA CARDIAC BIOMARKER MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 138. LATIN AMERICA CARDIAC BIOMARKER MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 139. LATIN AMERICA CARDIAC BIOMARKER MARKET SIZE, BY DIAGNOSIS, 2018-2024 (USD MILLION)
  • TABLE 140. LATIN AMERICA CARDIAC BIOMARKER MARKET SIZE, BY DIAGNOSIS, 2025-2032 (USD MILLION)
  • TABLE 141. LATIN AMERICA CARDIAC BIOMARKER MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 142. LATIN AMERICA CARDIAC BIOMARKER MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 143. EUROPE, MIDDLE EAST & AFRICA CARDIAC BIOMARKER MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 144. EUROPE, MIDDLE EAST & AFRICA CARDIAC BIOMARKER MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 145. EUROPE, MIDDLE EAST & AFRICA CARDIAC BIOMARKER MARKET SIZE, BY BIOMARKER TYPE, 2018-2024 (USD MILLION)
  • TABLE 146. EUROPE, MIDDLE EAST & AFRICA CARDIAC BIOMARKER MARKET SIZE, BY BIOMARKER TYPE, 2025-2032 (USD MILLION)
  • TABLE 147. EUROPE, MIDDLE EAST & AFRICA CARDIAC BIOMARKER MARKET SIZE, BY CLINICAL SETTING, 2018-2024 (USD MILLION)
  • TABLE 148. EUROPE, MIDDLE EAST & AFRICA CARDIAC BIOMARKER MARKET SIZE, BY CLINICAL SETTING, 2025-2032 (USD MILLION)
  • TABLE 149. EUROPE, MIDDLE EAST & AFRICA CARDIAC BIOMARKER MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 150. EUROPE, MIDDLE EAST & AFRICA CARDIAC BIOMARKER MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 151. EUROPE, MIDDLE EAST & AFRICA CARDIAC BIOMARKER MARKET SIZE, BY DIAGNOSIS, 2018-2024 (USD MILLION)
  • TABLE 152. EUROPE, MIDDLE EAST & AFRICA CARDIAC BIOMARKER MARKET SIZE, BY DIAGNOSIS, 2025-2032 (USD MILLION)
  • TABLE 153. EUROPE, MIDDLE EAST & AFRICA CARDIAC BIOMARKER MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 154. EUROPE, MIDDLE EAST & AFRICA CARDIAC BIOMARKER MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 155. EUROPE CARDIAC BIOMARKER MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 156. EUROPE CARDIAC BIOMARKER MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 157. EUROPE CARDIAC BIOMARKER MARKET SIZE, BY BIOMARKER TYPE, 2018-2024 (USD MILLION)
  • TABLE 158. EUROPE CARDIAC BIOMARKER MARKET SIZE, BY BIOMARKER TYPE, 2025-2032 (USD MILLION)
  • TABLE 159. EUROPE CARDIAC BIOMARKER MARKET SIZE, BY CLINICAL SETTING, 2018-2024 (USD MILLION)
  • TABLE 160. EUROPE CARDIAC BIOMARKER MARKET SIZE, BY CLINICAL SETTING, 2025-2032 (USD MILLION)
  • TABLE 161. EUROPE CARDIAC BIOMARKER MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 162. EUROPE CARDIAC BIOMARKER MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 163. EUROPE CARDIAC BIOMARKER MARKET SIZE, BY DIAGNOSIS, 2018-2024 (USD MILLION)
  • TABLE 164. EUROPE CARDIAC BIOMARKER MARKET SIZE, BY DIAGNOSIS, 2025-2032 (USD MILLION)
  • TABLE 165. EUROPE CARDIAC BIOMARKER MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 166. EUROPE CARDIAC BIOMARKER MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 167. MIDDLE EAST CARDIAC BIOMARKER MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 168. MIDDLE EAST CARDIAC BIOMARKER MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 169. MIDDLE EAST CARDIAC BIOMARKER MARKET SIZE, BY BIOMARKER TYPE, 2018-2024 (USD MILLION)
  • TABLE 170. MIDDLE EAST CARDIAC BIOMARKER MARKET SIZE, BY BIOMARKER TYPE, 2025-2032 (USD MILLION)
  • TABLE 171. MIDDLE EAST CARDIAC BIOMARKER MARKET SIZE, BY CLINICAL SETTING, 2018-2024 (USD MILLION)
  • TABLE 172. MIDDLE EAST CARDIAC BIOMARKER MARKET SIZE, BY CLINICAL SETTING, 2025-2032 (USD MILLION)
  • TABLE 173. MIDDLE EAST CARDIAC BIOMARKER MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 174. MIDDLE EAST CARDIAC BIOMARKER MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 175. MIDDLE EAST CARDIAC BIOMARKER MARKET SIZE, BY DIAGNOSIS, 2018-2024 (USD MILLION)
  • TABLE 176. MIDDLE EAST CARDIAC BIOMARKER MARKET SIZE, BY DIAGNOSIS, 2025-2032 (USD MILLION)
  • TABLE 177. MIDDLE EAST CARDIAC BIOMARKER MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 178. MIDDLE EAST CARDIAC BIOMARKER MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 179. AFRICA CARDIAC BIOMARKER MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 180. AFRICA CARDIAC BIOMARKER MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 181. AFRICA CARDIAC BIOMARKER MARKET SIZE, BY BIOMARKER TYPE, 2018-2024 (USD MILLION)
  • TABLE 182. AFRICA CARDIAC BIOMARKER MARKET SIZE, BY BIOMARKER TYPE, 2025-2032 (USD MILLION)
  • TABLE 183. AFRICA CARDIAC BIOMARKER MARKET SIZE, BY CLINICAL SETTING, 2018-2024 (USD MILLION)
  • TABLE 184. AFRICA CARDIAC BIOMARKER MARKET SIZE, BY CLINICAL SETTING, 2025-2032 (USD MILLION)
  • TABLE 185. AFRICA CARDIAC BIOMARKER MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 186. AFRICA CARDIAC BIOMARKER MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 187. AFRICA CARDIAC BIOMARKER MARKET SIZE, BY DIAGNOSIS, 2018-2024 (USD MILLION)
  • TABLE 188. AFRICA CARDIAC BIOMARKER MARKET SIZE, BY DIAGNOSIS, 2025-2032 (USD MILLION)
  • TABLE 189. AFRICA CARDIAC BIOMARKER MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 190. AFRICA CARDIAC BIOMARKER MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 191. ASIA-PACIFIC CARDIAC BIOMARKER MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 192. ASIA-PACIFIC CARDIAC BIOMARKER MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 193. ASIA-PACIFIC CARDIAC BIOMARKER MARKET SIZE, BY BIOMARKER TYPE, 2018-2024 (USD MILLION)
  • TABLE 194. ASIA-PACIFIC CARDIAC BIOMARKER MARKET SIZE, BY BIOMARKER TYPE, 2025-2032 (USD MILLION)
  • TABLE 195. ASIA-PACIFIC CARDIAC BIOMARKER MARKET SIZE, BY CLINICAL SETTING, 2018-2024 (USD MILLION)
  • TABLE 196. ASIA-PACIFIC CARDIAC BIOMARKER MARKET SIZE, BY CLINICAL SETTING, 2025-2032 (USD MILLION)
  • TABLE 197. ASIA-PACIFIC CARDIAC BIOMARKER MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 198. ASIA-PACIFIC CARDIAC BIOMARKER MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 199. ASIA-PACIFIC CARDIAC BIOMARKER MARKET SIZE, BY DIAGNOSIS, 2018-2024 (USD MILLION)
  • TABLE 200. ASIA-PACIFIC CARDIAC BIOMARKER MARKET SIZE, BY DIAGNOSIS, 2025-2032 (USD MILLION)
  • TABLE 201. ASIA-PACIFIC CARDIAC BIOMARKER MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 202. ASIA-PACIFIC CARDIAC BIOMARKER MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL CARDIAC BIOMARKER MARKET SIZE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL CARDIAC BIOMARKER MARKET SIZE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 205. ASEAN CARDIAC BIOMARKER MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 206. ASEAN CARDIAC BIOMARKER MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 207. ASEAN CARDIAC BIOMARKER MARKET SIZE, BY BIOMARKER TYPE, 2018-2024 (USD MILLION)
  • TABLE 208. ASEAN CARDIAC BIOMARKER MARKET SIZE, BY BIOMARKER TYPE, 2025-2032 (USD MILLION)
  • TABLE 209. ASEAN CARDIAC BIOMARKER MARKET SIZE, BY CLINICAL SETTING, 2018-2024 (USD MILLION)
  • TABLE 210. ASEAN CARDIAC BIOMARKER MARKET SIZE, BY CLINICAL SETTING, 2025-2032 (USD MILLION)
  • TABLE 211. ASEAN CARDIAC BIOMARKER MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 212. ASEAN CARDIAC BIOMARKER MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 213. ASEAN CARDIAC BIOMARKER MARKET SIZE, BY DIAGNOSIS, 2018-2024 (USD MILLION)
  • TABLE 214. ASEAN CARDIAC BIOMARKER MARKET SIZE, BY DIAGNOSIS, 2025-2032 (USD MILLION)
  • TABLE 215. ASEAN CARDIAC BIOMARKER MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 216. ASEAN CARDIAC BIOMARKER MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 217. GCC CARDIAC BIOMARKER MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 218. GCC CARDIAC BIOMARKER MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 219. GCC CARDIAC BIOMARKER MARKET SIZE, BY BIOMARKER TYPE, 2018-2024 (USD MILLION)
  • TABLE 220. GCC CARDIAC BIOMARKER MARKET SIZE, BY BIOMARKER TYPE, 2025-2032 (USD MILLION)
  • TABLE 221. GCC CARDIAC BIOMARKER MARKET SIZE, BY CLINICAL SETTING, 2018-2024 (USD MILLION)
  • TABLE 222. GCC CARDIAC BIOMARKER MARKET SIZE, BY CLINICAL SETTING, 2025-2032 (USD MILLION)
  • TABLE 223. GCC CARDIAC BIOMARKER MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 224. GCC CARDIAC BIOMARKER MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 225. GCC CARDIAC BIOMARKER MARKET SIZE, BY DIAGNOSIS, 2018-2024 (USD MILLION)
  • TABLE 226. GCC CARDIAC BIOMARKER MARKET SIZE, BY DIAGNOSIS, 2025-2032 (USD MILLION)
  • TABLE 227. GCC CARDIAC BIOMARKER MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 228. GCC CARDIAC BIOMARKER MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 229. EUROPEAN UNION CARDIAC BIOMARKER MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 230. EUROPEAN UNION CARDIAC BIOMARKER MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 231. EUROPEAN UNION CARDIAC BIOMARKER MARKET SIZE, BY BIOMARKER TYPE, 2018-2024 (USD MILLION)
  • TABLE 232. EUROPEAN UNION CARDIAC BIOMARKER MARKET SIZE, BY BIOMARKER TYPE, 2025-2032 (USD MILLION)
  • TABLE 233. EUROPEAN UNION CARDIAC BIOMARKER MARKET SIZE, BY CLINICAL SETTING, 2018-2024 (USD MILLION)
  • TABLE 234. EUROPEAN UNION CARDIAC BIOMARKER MARKET SIZE, BY CLINICAL SETTING, 2025-2032 (USD MILLION)
  • TABLE 235. EUROPEAN UNION CARDIAC BIOMARKER MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 236. EUROPEAN UNION CARDIAC BIOMARKER MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 237. EUROPEAN UNION CARDIAC BIOMARKER MARKET SIZE, BY DIAGNOSIS, 2018-2024 (USD MILLION)
  • TABLE 238. EUROPEAN UNION CARDIAC BIOMARKER MARKET SIZE, BY DIAGNOSIS, 2025-2032 (USD MILLION)
  • TABLE 239. EUROPEAN UNION CARDIAC BIOMARKER MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 240. EUROPEAN UNION CARDIAC BIOMARKER MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 241. BRICS CARDIAC BIOMARKER MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 242. BRICS CARDIAC BIOMARKER MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 243. BRICS CARDIAC BIOMARKER MARKET SIZE, BY BIOMARKER TYPE, 2018-2024 (USD MILLION)
  • TABLE 244. BRICS CARDIAC BIOMARKER MARKET SIZE, BY BIOMARKER TYPE, 2025-2032 (USD MILLION)
  • TABLE 245. BRICS CARDIAC BIOMARKER MARKET SIZE, BY CLINICAL SETTING, 2018-2024 (USD MILLION)
  • TABLE 246. BRICS CARDIAC BIOMARKER MARKET SIZE, BY CLINICAL SETTING, 2025-2032 (USD MILLION)
  • TABLE 247. BRICS CARDIAC BIOMARKER MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 248. BRICS CARDIAC BIOMARKER MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 249. BRICS CARDIAC BIOMARKER MARKET SIZE, BY DIAGNOSIS, 2018-2024 (USD MILLION)
  • TABLE 250. BRICS CARDIAC BIOMARKER MARKET SIZE, BY DIAGNOSIS, 2025-2032 (USD MILLION)
  • TABLE 251. BRICS CARDIAC BIOMARKER MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 252. BRICS CARDIAC BIOMARKER MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 253. G7 CARDIAC BIOMARKER MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 254. G7 CARDIAC BIOMARKER MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 255. G7 CARDIAC BIOMARKER MARKET SIZE, BY BIOMARKER TYPE, 2018-2024 (USD MILLION)
  • TABLE 256. G7 CARDIAC BIOMARKER MARKET SIZE, BY BIOMARKER TYPE, 2025-2032 (USD MILLION)
  • TABLE 257. G7 CARDIAC BIOMARKER MARKET SIZE, BY CLINICAL SETTING, 2018-2024 (USD MILLION)
  • TABLE 258. G7 CARDIAC BIOMARKER MARKET SIZE, BY CLINICAL SETTING, 2025-2032 (USD MILLION)
  • TABLE 259. G7 CARDIAC BIOMARKER MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 260. G7 CARDIAC BIOMARKER MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 261. G7 CARDIAC BIOMARKER MARKET SIZE, BY DIAGNOSIS, 2018-2024 (USD MILLION)
  • TABLE 262. G7 CARDIAC BIOMARKER MARKET SIZE, BY DIAGNOSIS, 2025-2032 (USD MILLION)
  • TABLE 263. G7 CARDIAC BIOMARKER MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 264. G7 CARDIAC BIOMARKER MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 265. NATO CARDIAC BIOMARKER MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 266. NATO CARDIAC BIOMARKER MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 267. NATO CARDIAC BIOMARKER MARKET SIZE, BY BIOMARKER TYPE, 2018-2024 (USD MILLION)
  • TABLE 268. NATO CARDIAC BIOMARKER MARKET SIZE, BY BIOMARKER TYPE, 2025-2032 (USD MILLION)
  • TABLE 269. NATO CARDIAC BIOMARKER MARKET SIZE, BY CLINICAL SETTING, 2018-2024 (USD MILLION)
  • TABLE 270. NATO CARDIAC BIOMARKER MARKET SIZE, BY CLINICAL SETTING, 2025-2032 (USD MILLION)
  • TABLE 271. NATO CARDIAC BIOMARKER MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 272. NATO CARDIAC BIOMARKER MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 273. NATO CARDIAC BIOMARKER MARKET SIZE, BY DIAGNOSIS, 2018-2024 (USD MILLION)
  • TABLE 274. NATO CARDIAC BIOMARKER MARKET SIZE, BY DIAGNOSIS, 2025-2032 (USD MILLION)
  • TABLE 275. NATO CARDIAC BIOMARKER MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 276. NATO CARDIAC BIOMARKER MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 277. GLOBAL CARDIAC BIOMARKER MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 278. GLOBAL CARDIAC BIOMARKER MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 279. UNITED STATES CARDIAC BIOMARKER MARKET SIZE, BY BIOMARKER TYPE, 2018-2024 (USD MILLION)
  • TABLE 280. UNITED STATES CARDIAC BIOMARKER MARKET SIZE, BY BIOMARKER TYPE, 2025-2032 (USD MILLION)
  • TABLE 281. UNITED STATES CARDIAC BIOMARKER MARKET SIZE, BY CLINICAL SETTING, 2018-2024 (USD MILLION)
  • TABLE 282. UNITED STATES CARDIAC BIOMARKER MARKET SIZE, BY CLINICAL SETTING, 2025-2032 (USD MILLION)
  • TABLE 283. UNITED STATES CARDIAC BIOMARKER MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 284. UNITED STATES CARDIAC BIOMARKER MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 285. UNITED STATES CARDIAC BIOMARKER MARKET SIZE, BY DIAGNOSIS, 2018-2024 (USD MILLION)
  • TABLE 286. UNITED STATES CARDIAC BIOMARKER MARKET SIZE, BY DIAGNOSIS, 2025-2032 (USD MILLION)
  • TABLE 287. UNITED STATES CARDIAC BIOMARKER MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 288. UNITED STATES CARDIAC BIOMARKER MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 289. CANADA CARDIAC BIOMARKER MARKET SIZE, BY BIOMARKER TYPE, 2018-2024 (USD MILLION)
  • TABLE 290. CANADA CARDIAC BIOMARKER MARKET SIZE, BY BIOMARKER TYPE, 2025-2032 (USD MILLION)
  • TABLE 291. CANADA CARDIAC BIOMARKER MARKET SIZE, BY CLINICAL SETTING, 2018-2024 (USD MILLION)
  • TABLE 292. CANADA CARDIAC BIOMARKER MARKET SIZE, BY CLINICAL SETTING, 2025-2032 (USD MILLION)
  • TABLE 293. CANADA CARDIAC BIOMARKER MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 294. CANADA CARDIAC BIOMARKER MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 295. CANADA CARDIAC BIOMARKER MARKET SIZE, BY DIAGNOSIS, 2018-2024 (USD MILLION)
  • TABLE 296. CANADA CARDIAC BIOMARKER MARKET SIZE, BY DIAGNOSIS, 2025-2032 (USD MILLION)
  • TABLE 297. CANADA CARDIAC BIOMARKER MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 298. CANADA CARDIAC BIOMARKER MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 299. MEXICO CARDIAC BIOMARKER MARKET SIZE, BY BIOMARKER TYPE, 2018-2024 (USD MILLION)
  • TABLE 300. MEXICO CARDIAC BIOMARKER MARKET SIZE, BY BIOMARKER TYPE, 2025-2032 (USD MILLION)
  • TABLE 301. MEXICO CARDIAC BIOMARKER MARKET SIZE, BY CLINICAL SETTING, 2018-2024 (USD MILLION)
  • TABLE 302. MEXICO CARDIAC BIOMARKER MARKET SIZE, BY CLINICAL SETTING, 2025-2032 (USD MILLION)
  • TABLE 303. MEXICO CARDIAC BIOMARKER MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 304. MEXICO CARDIAC BIOMARKER MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 305. MEXICO CARDIAC BIOMARKER MARKET SIZE, BY DIAGNOSIS, 2018-2024 (USD MILLION)
  • TABLE 306. MEXICO CARDIAC BIOMARKER MARKET SIZE, BY DIAGNOSIS, 2025-2032 (USD MILLION)
  • TABLE 307. MEXICO CARDIAC BIOMARKER MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 308. MEXICO CARDIAC BIOMARKER MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 309. BRAZIL CARDIAC BIOMARKER MARKET SIZE, BY BIOMARKER TYPE, 2018-2024 (USD MILLION)
  • TABLE 310. BRAZIL CARDIAC BIOMARKER MARKET SIZE, BY BIOMARKER TYPE, 2025-2032 (USD MILLION)
  • TABLE 311. BRAZIL CARDIAC BIOMARKER MARKET SIZE, BY CLINICAL SETTING, 2018-2024 (USD MILLION)
  • TABLE 312. BRAZIL CARDIAC BIOMARKER MARKET SIZE, BY CLINICAL SETTING, 2025-2032 (USD MILLION)
  • TABLE 313. BRAZIL CARDIAC BIOMARKER MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 314. BRAZIL CARDIAC BIOMARKER MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 315. BRAZIL CARDIAC BIOMARKER MARKET SIZE, BY DIAGNOSIS, 2018-2024 (USD MILLION)
  • TABLE 316. BRAZIL CARDIAC BIOMARKER MARKET SIZE, BY DIAGNOSIS, 2025-2032 (USD MILLION)
  • TABLE 317. BRAZIL CARDIAC BIOMARKER MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 318. BRAZIL CARDIAC BIOMARKER MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 319. UNITED KINGDOM CARDIAC BIOMARKER MARKET SIZE, BY BIOMARKER TYPE, 2018-2024 (USD MILLION)
  • TABLE 320. UNITED KINGDOM CARDIAC BIOMARKER MARKET SIZE, BY BIOMARKER TYPE, 2025-2032 (USD MILLION)
  • TABLE 321. UNITED KINGDOM CARDIAC BIOMARKER MARKET SIZE, BY CLINICAL SETTING, 2018-2024 (USD MILLION)
  • TABLE 322. UNITED KINGDOM CARDIAC BIOMARKER MARKET SIZE, BY CLINICAL SETTING, 2025-2032 (USD MILLION)
  • TABLE 323. UNITED KINGDOM CARDIAC BIOMARKER MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 324. UNITED KINGDOM CARDIAC BIOMARKER MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 325. UNITED KINGDOM CARDIAC BIOMARKER MARKET SIZE, BY DIAGNOSIS, 2018-2024 (USD MILLION)
  • TABLE 326. UNITED KINGDOM CARDIAC BIOMARKER MARKET SIZE, BY DIAGNOSIS, 2025-2032 (USD MILLION)
  • TABLE 327. UNITED KINGDOM CARDIAC BIOMARKER MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 328. UNITED KINGDOM CARDIAC BIOMARKER MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 329. GERMANY CARDIAC BIOMARKER MARKET SIZE, BY BIOMARKER TYPE, 2018-2024 (USD MILLION)
  • TABLE 330. GERMANY CARDIAC BIOMARKER MARKET SIZE, BY BIOMARKER TYPE, 2025-2032 (USD MILLION)
  • TABLE 331. GERMANY CARDIAC BIOMARKER MARKET SIZE, BY CLINICAL SETTING, 2018-2024 (USD MILLION)
  • TABLE 332. GERMANY CARDIAC BIOMARKER MARKET SIZE, BY CLINICAL SETTING, 2025-2032 (USD MILLION)
  • TABLE 333. GERMANY CARDIAC BIOMARKER MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 334. GERMANY CARDIAC BIOMARKER MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 335. GERMANY CARDIAC BIOMARKER MARKET SIZE, BY DIAGNOSIS, 2018-2024 (USD MILLION)
  • TABLE 336. GERMANY CARDIAC BIOMARKER MARKET SIZE, BY DIAGNOSIS, 2025-2032 (USD MILLION)
  • TABLE 337. GERMANY CARDIAC BIOMARKER MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 338. GERMANY CARDIAC BIOMARKER MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 339. FRANCE CARDIAC BIOMARKER MARKET SIZE, BY BIOMARKER TYPE, 2018-2024 (USD MILLION)
  • TABLE 340. FRANCE CARDIAC BIOMARKER MARKET SIZE, BY BIOMARKER TYPE, 2025-2032 (USD MILLION)
  • TABLE 341. FRANCE CARDIAC BIOMARKER MARKET SIZE, BY CLINICAL SETTING, 2018-2024 (USD MILLION)
  • TABLE 342. FRANCE CARDIAC BIOMARKER MARKET SIZE, BY CLINICAL SETTING, 2025-2032 (USD MILLION)
  • TABLE 343. FRANCE CARDIAC BIOMARKER MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 344. FRANCE CARDIAC BIOMARKER MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 345. FRANCE CARDIAC BIOMARKER MARKET SIZE, BY DIAGNOSIS, 2018-2024 (USD MILL